<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3630">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629703</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-061</org_study_id>
    <nct_id>NCT04629703</nct_id>
  </id_info>
  <brief_title>Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a double-blind, randomized, placebo-controlled, adaptive design, multi-center,&#xD;
      Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to severe/critical disease within 29 days of first dose of study treatment</measure>
    <time_frame>29 days</time_frame>
    <description>Progression to severe/critical disease within 29 days of first dose of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects transferred into the intensive care unit (ICU) or who died prior to Day 29</measure>
    <time_frame>29 days</time_frame>
    <description>Proportion of subjects transferred into the intensive care unit (ICU) or who died prior to Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of calendar days hospitalized through Day 29</measure>
    <time_frame>29 days</time_frame>
    <description>Total number of calendar days hospitalized through Day 29</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Covid19</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <condition>SARS Pneumonia</condition>
  <condition>SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere</condition>
  <condition>Pneumonia</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Fostamatinib (150 mg twice daily for 14 days) + Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib (150 mg twice daily for 14 days) + Standard of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (twice daily for 14 days) + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (twice daily for 14 days) + Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib (150 mg twice daily) for 14 days and Standard of Care</description>
    <arm_group_label>Fostamatinib (150 mg twice daily for 14 days) + Standard of Care</arm_group_label>
    <other_name>Fostamatinib disodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (twice daily) for 14 days and Standard of Care</description>
    <arm_group_label>Placebo (twice daily for 14 days) + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age at screening.&#xD;
&#xD;
          -  The subject or a legally authorized representative has provided written informed&#xD;
             consent.&#xD;
&#xD;
          -  Hospitalized COVID-19 subjects without respiratory failure who are either not&#xD;
             receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal&#xD;
             prongs.&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female subjects with SARS-CoV-2 infection&#xD;
             documented by a hospital approved diagnostic test (eg, a Food and Drug Administration&#xD;
             authorized test in the US) within 7 days prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating female of childbearing potential.&#xD;
&#xD;
          -  Use of extracorporeal membrane oxygenation (ECMO) or ARDS.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure [BP] ≥160 mmHg and/or diastolic BP&#xD;
             ≥100 mmHg), unstable angina, congestive heart failure of New York Heart Association&#xD;
             classification III or IV, serious cardiac arrhythmia requiring treatment.&#xD;
&#xD;
          -  History of myocardial infarction within 3 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>SARS-Associated Coronavirus Pneumonia</keyword>
  <keyword>Pneumonia, Viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

